USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ADVAXIS, INC.
Address:
675 Highway one
North Brunswick, NJ 08902 3378
Phone:
N/A
URL:
N/A
EIN:
20563870
DUNS:
140232815
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,020,938.00 3
STTR Phase I $506,452.00 2

Award List:

Novel Immunotherapy for the treatment of cervical cancer

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Despite the demonstrated efficacy of screening programs, cervical cancer continues to be a significant health issue. In 1999 alone, 12,800 women were be diagnosed with advanced cervical cancer in the U.S. and approximately 4,000 died of the disease. These women… More

Listeria PEST Sequence Fusion Proteins as Tumor Vaccines

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$210,199.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In the battle against cancer, therapeutic vaccines are proving to be a promising new approach. Many approaches focus on delivery of therapeutic vaccines via live vectors. However there is still a need to develop novel platform technologies for the production… More

Bacterial vector vaccine: Her-2/neu expressing tumors

Award Year / Program / Phase:
2005 / STTR / Phase I
Award Amount:
$256,389.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF PENNSYLVANIA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Advaxis will develop a novel Listeria monocytogenes based vaccine against the human HER-2/neu protein that will be a safe and effective therapeutic vaccine for the treatment of HER-2/neu overexpressing breast carcinomas. Breast cancer, the most common type of… More

Antiangiogenic and antitumoral therapy delivered by a dual-expression L. monocyto

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$210,739.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Breast cancer is the second most common type of cancer in females, causing over 40,000 deaths in the United States annually. Recently, cancer vaccines have arisen as a potential therapy and several target antigens have been identified in Breast cancer, including… More